Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/2757
Registo completo
Campo DCValorIdioma
dc.contributor.authorRobalo-Cordeiro, C-
dc.contributor.authorCampos, P-
dc.contributor.authorCarvalho, L-
dc.contributor.authorBorba, A-
dc.contributor.authorClemente, S-
dc.contributor.authorFreitas, S-
dc.contributor.authorFurtado, S-
dc.contributor.authorJesus, JM-
dc.contributor.authorLeal, C-
dc.contributor.authorMarques, A-
dc.contributor.authorMelo, N-
dc.contributor.authorSouto-Moura, C-
dc.contributor.authorNeves, S-
dc.contributor.authorSousa, V-
dc.contributor.authorSantos, A-
dc.contributor.authorMorais, A-
dc.date.accessioned2017-10-12T14:14:38Z-
dc.date.available2017-10-12T14:14:38Z-
dc.date.issued2017-
dc.identifier.citationRev Port Pneumol (2006). 2017 Sep - Oct;23(5):287-293pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2757-
dc.description.abstractIdiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that up to now has been associated with a poor prognosis. However, the results of the INPULSIS and ASCEND trials and the approval of nintedanib and pirfenidone have marked the beginning of a new era for IPF patients. Questions remain, however. Should these drugs be used earlier? What effect will they have on more severe disease? Will their effects last beyond the trial period? This manuscript is the outcome of a multidisciplinary meeting between pulmonology, radiology, and pathology clinicians on the use of antifibrotic agents in IPF. In our opinion, the existing data show that pirfenidone and nintedanib slow functional decline in early stages of disease. These drugs also appear to result in therapeutic benefits when administered to patients with advanced disease at diagnosis and maintain effective over time. The data also suggest that continuing antifibrotic therapy after disease progression may confer benefits, but more evidence is needed. Early diagnosis and treatment are crucial for reducing functional decline, slowing disease progression, and improving quality of life.pt_PT
dc.language.isoengpt_PT
dc.rightsopenAccesspt_PT
dc.subjectHSM PNEUpt_PT
dc.subjectHSM IMApt_PT
dc.subjectIdiopathic Pulmonary Fibrosis-
dc.subjectInterstitial Lung Disease-
dc.titleIdiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy: Searching for New Opportunities Grounded in Evidencept_PT
dc.typearticlept_PT
dc.peerreviewedyespt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
degois.publication.firstPage287pt_PT
degois.publication.lastPage293pt_PT
degois.publication.issue5pt_PT
degois.publication.titleRevista Portuguesa de Pneumologiapt_PT
degois.publication.volume23pt_PT
dc.identifier.doi10.1016/j.rppnen.2017.05.005pt_PT
Aparece nas colecções:IMA - Artigos
PNEU - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
RPP 287.pdf907,6 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.